Optimization of Dose Selection for Non-Vitamin K Antagonist Oral Anticoagulants
The era of oral anticoagulation dawned in the 1940s, when the first clinical trials of the drug that would become known as warfarin were conducted [1,2]. The introduction of warfarin into practice in the 1950s revolutionized the care of patients with or at risk for thromboembolism [3]. In the ensuing decades, warfarin therapy was shown to be effective for reducing the risk of a variety of thromboembolic disorders, including stroke and thromboembolism associated with atrial fibrillation (AF) [4].
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: James E. Tisdale Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Clinical Trials | Coumadin | Heart | Stroke | Thrombosis | Vitamin K | Vitamins | Warfarin